'For the quarter ending March 2024, consolidated net sales (including other operating income) of Dr Reddys Laboratories has increased 12.65% to Rs 7113.8 crore compared to quarter ended March 2023.  Sales of Pharmaceutical Services segment has gone up 12.76% to Rs 1,172.50 crore (accounting for 15.75% of total sales).  Sales of Global Generics segment has gone up 12.88% to Rs 6,128.90 crore (accounting for 82.33% of total sales).  Sales of Others segment has gone up 53.71% to Rs 143.10 crore (accounting for 1.92% of total sales).  Inter-segment sales rose Rs 247.40 crore to Rs 330.70 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 15.23% to Rs 4,148.80 crore.  PBIT of Pharmaceutical Services segment rose 19.24% to Rs 234.90 crore (accounting for 5.66% of total PBIT).  PBIT of Global Generics segment rose 13.25% to Rs 3,793.70 crore (accounting for 91.44% of total PBIT).&nb...

• 

  (24-Apr-2025)

  Hindustan Unilever

  OP up 2.38%
• 

  (24-Apr-2025)

  Syngene International

  NP down 2.81%
• 

  (24-Apr-2025)

  Tata Consumer Products

  OP down 1.37%
• 

  (24-Apr-2025)

  Dalmia Bharat

  PAT up 38.1% YoY to Rs 435 crore in Q4FY2025